摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(isobutylamino)-1-phenylethanol | 55474-91-4

中文名称
——
中文别名
——
英文名称
2-(isobutylamino)-1-phenylethanol
英文别名
2-[(2-Methylpropyl)amino]-1-phenylethan-1-ol;2-(2-methylpropylamino)-1-phenylethanol
2-(isobutylamino)-1-phenylethanol化学式
CAS
55474-91-4
化学式
C12H19NO
mdl
MFCD05263330
分子量
193.289
InChiKey
UERFLMOOWGTPDV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    289.9±7.0 °C(Predicted)
  • 密度:
    0.987±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    32.3
  • 氢给体数:
    2
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(isobutylamino)-1-phenylethanol溶剂黄146 、 sodium nitrite 作用下, 以 为溶剂, 生成 N-(2-hydroxy-2-phenylethyl)-N-(2-methylpropyl)nitrous amide
    参考文献:
    名称:
    Synthesis, in Vitro Activity, and Three-Dimensional Quantitative Structure−Activity Relationship of Novel Hydrazine Inhibitors of Human Vascular Adhesion Protein-1
    摘要:
    Vascular adhesion protein-1 (VAP-1) belongs to the semicarbazide-sensitive amine oxidases (SSAOs) that convert amines into aldehydes. SSAOs are distinct from the mammalian monoamine oxidases (MAOs), but their substrate specificities are partly overlapping. VAP-1 has been proposed as a target for anti-inflammatory drug therapy because of its role in leukocyte adhesion to endothelium. Here, we describe the synthesis and in vitro activities of novel series of VAP-1 selective inhibitors. In addition, the molecular dynamics simulations performed for VAP-1 reveal that the movements of Met211, Ser496, and especially Leu469 can enlarge the ligand-binding pocket, allowing larger ligands than those seen in the crystal structures to bind. Combining the data from molecular dynamics simulations, docking, and in vitro measurements, the three-dimensional quantitative structure-activity relationship (3D QSAR) models for VAP-1 (q(LOO)(2): 0.636; r(2:) 0.828) and MAOs (q(LOO)(2): 0.749, r(2): 0.840) were built and employed in the development of selective VAP-1 inhibitors.
    DOI:
    10.1021/jm100337z
  • 作为产物:
    描述:
    2-isopropyl-5-phenyl-1,3-oxazolidine 在 sodium tetrahydroborate 作用下, 生成 2-(isobutylamino)-1-phenylethanol
    参考文献:
    名称:
    Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
    摘要:
    这项发明涉及2-芳基亚胺杂环化合物,包括2-芳基亚胺-1,3-噻唑啉、2-芳基亚胺-2,3,4,5-四氢-1,3-噻嗪、2-芳基亚胺-1,3-噻唑啉-4-酮、2-芳基亚胺-1,3-噻唑啉-5-酮和2-芳基亚胺-1,3-噁唑啉,以及它们在调节孕激素受体介导的过程中的应用,以及用于这类治疗的药物组合物。
    公开号:
    US06353006B1
点击查看最新优质反应信息

文献信息

  • Sulfonyl Fluorides as Alternative to Sulfonyl Chlorides in Parallel Synthesis of Aliphatic Sulfonamides
    作者:Andrey V. Bogolubsky、Yurii S. Moroz、Pavel K. Mykhailiuk、Sergey E. Pipko、Anzhelika I. Konovets、Irina V. Sadkova、Andrey Tolmachev
    DOI:10.1021/co400164z
    日期:2014.4.14
    types of aliphatic sulfonyl halides (Cl versus F) were compared in parallel synthesis of sulfonamides derived from aliphatic amines. Aliphatic sulfonyl fluorides showed good results with amines bearing an additional functionality, while the corresponding chlorides failed. Both sulfonyl halides were effective in the reactions with amines having an easily accessible amino group. Aliphatic sulfonyl chlorides
    在平行合成衍生自脂族胺的磺酰胺中,比较了两种类型的脂族磺酰卤(Cl与F)。脂肪族磺酰氟与带有额外官能团的胺显示出良好的效果,而相应的氯化物却不合格。两种磺酰基卤化物在与具有易于接近的氨基的胺的反应中都是有效的。脂肪族磺酰氯与带有空间位阻氨基的胺有效反应,而相应的氟化物显示低活性。
  • [EN] AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES<br/>[FR] IMIDAZOPYRIDAZINES SUBSTITUÉES PAR AMINO
    申请人:BAYER IP GMBH
    公开号:WO2013144189A1
    公开(公告)日:2013-10-03
    The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)的氨基取代咪唑吡啶化合物,其中A、R1、R2、R3、R4、R5和n如权利要求中所定义,以及制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包括所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是用作唯一药剂或与其他活性成分结合。
  • AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES
    申请人:Bayer Intellectual Property GmbH
    公开号:US20150087631A1
    公开(公告)日:2015-03-26
    The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)的氨基取代咪唑吡啶化合物,其中A、R1、R2、R3、R4、R5和n如权利要求中所定义,以及制备所述化合物的方法,用于制备所述化合物的有用中间体化合物,包括所述化合物的药物组合物和组合物,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是用作唯一药剂或与其他活性成分组合使用,治疗或预防过度增殖和/或血管生成紊乱。
  • [EN] SUBSTITUTED AMINOIMIDAZOPYRIDAZINES<br/>[FR] AMINOIMIDAZOPYRIDAZINES SUBSTITUÉES
    申请人:BAYER IP GMBH
    公开号:WO2012163942A1
    公开(公告)日:2012-12-06
    The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I) : in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    本发明涉及一般式(I)的取代氨基咪唑吡啶嗪化合物,其中A、R1、R2、R3和R4如权利要求中定义的那样,以及制备所述化合物的方法,包括所述化合物的药物组合物和组合物,以及使用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗或预防高增殖和/或血管生成紊乱的药物组合物,作为单一药剂或与其他活性成分组合使用。
  • Regioselective N-methyl carbon lithiation of N-boc-methylalkylamines. Expedient synthesis of unsymmetrical amines
    作者:Victor Snieckus、Mark Rogers-Evans、Peter Beak、Won Koo Lee、Eul Kyun Yum、John Freskos
    DOI:10.1016/s0040-4039(00)73113-3
    日期:1994.6
    The regioselective lithiation and functionalization at the N-methyl group of N-t-Boc-N-methylalkylamines 3 and 5 are shown with a variety of electrophiles to give products 4 and 6, respectively, thus providing a convenient methodology for the elaboration of unsymmetrical amines.
    N- t -Boc- N-甲基烷基胺3和5在N-甲基的区域选择性锂化和官能化显示了各种亲电试剂,分别得到产物4和6,从而为阐述不对称现象提供了便利的方法胺类。
查看更多

同类化合物

(N-(2-甲基丙-2-烯-1-基)乙烷-1,2-二胺) (4-(苄氧基)-2-(哌啶-1-基)吡啶咪丁-5-基)硼酸 (11-巯基十一烷基)-,,-三甲基溴化铵 鼠立死 鹿花菌素 鲸蜡醇硫酸酯DEA盐 鲸蜡硬脂基二甲基氯化铵 鲸蜡基胺氢氟酸盐 鲸蜡基二甲胺盐酸盐 高苯丙氨醇 高箱鲀毒素 高氯酸5-(二甲氨基)-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-2-甲基吡啶正离子 高氯酸2-氯-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-6-甲基吡啶正离子 高氯酸2-(丙烯酰基氧基)-N,N,N-三甲基乙铵 马诺地尔 马来酸氢十八烷酯 马来酸噻吗洛尔EP杂质C 马来酸噻吗洛尔 马来酸倍他司汀 顺式环己烷-1,3-二胺盐酸盐 顺式氯化锆二乙腈 顺式吡咯烷-3,4-二醇盐酸盐 顺式双(3-甲氧基丙腈)二氯铂(II) 顺式3,4-二氟吡咯烷盐酸盐 顺式1-甲基环丙烷1,2-二腈 顺式-二氯-反式-二乙酸-氨-环己胺合铂 顺式-二抗坏血酸(外消旋-1,2-二氨基环己烷)铂(II)水合物 顺式-N,2-二甲基环己胺 顺式-4-甲氧基-环己胺盐酸盐 顺式-4-环己烯-1.2-二胺 顺式-4-氨基-2,2,2-三氟乙酸环己酯 顺式-2-甲基环己胺 顺式-2-(苯基氨基)环己醇 顺式-2-(氨基甲基)-1-苯基环丙烷羧酸盐酸盐 顺式-1,3-二氨基环戊烷 顺式-1,2-环戊烷二胺 顺式-1,2-环丁腈 顺式-1,2-双氨甲基环己烷 顺式--N,N'-二甲基-1,2-环己二胺 顺式-(R,S)-1,2-二氨基环己烷铂硫酸盐 顺式-(2-氨基-环戊基)-甲醇 顺-2-戊烯腈 顺-1,3-环己烷二胺 顺-1,3-双(氨甲基)环己烷 顺,顺-丙二腈 非那唑啉 靛酚钠盐 靛酚 霜霉威盐酸盐 霜脲氰